Juvenile Myelomonocytic Leukemia

This is a type of leukemia that affects young children. It's a serious condition where the bone marrow doesn't make enough healthy blood cells. The leukemia cells are a mix of myeloid and monocytoid cells. It's called 'juvenile' because it affects children.

Condition

What people with Juvenile Myelomonocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Juvenile Myelomonocytic Leukemia?

NameHow it went

About Juvenile Myelomonocytic Leukemia

What It Is

Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of infants and young children. It is most often diagnosed around age 2 and is about twice as common in boys. In JMML, the bone marrow makes too many monocytes and related white blood cells. These cells build up in the blood and in organs such as the spleen and liver, while the marrow makes too few healthy red blood cells and platelets. Children often have a swollen belly from a large spleen and liver, along with fever, paleness, tiredness, easy bruising, swollen lymph nodes or a skin rash. The abnormal cells can also settle in the lungs and cause cough or breathing difficulty. JMML sits between two families of blood disorders: like a myeloproliferative disease it involves overproduction of cells, and like a myelodysplastic syndrome many of those cells do not mature or work properly. It is distinct from the more common childhood leukemias and is treated differently.

Causes & Risk Factors

JMML is driven by changes in genes that control a cell-growth signaling route called the RAS pathway. More than 90 percent of children with JMML have a change in one of five genes in this pathway (PTPN11, NRAS, KRAS, NF1 or CBL), which leaves the growth signal switched on. In about two-thirds of children, the gene change arose only in the blood-forming cells and was not inherited. In about one-third, the child was born with a gene change that is part of a broader genetic condition. Noonan syndrome, neurofibromatosis type 1 and CBL syndrome are the main ones. Having one of these conditions raises the chance of JMML, but most children with them never develop it. Nothing parents did or did not do causes JMML.

How It's Diagnosed

JMML is usually suspected when a young child has a large spleen and blood tests show a high white blood cell count with too many monocytes, along with anemia (low red blood cells) and low platelets. Another clue is a high level of fetal hemoglobin, a form of hemoglobin normally made before birth that declines over the first year or so. A bone marrow test, in which a small sample of marrow is taken from the hip bone, shows the overgrowth of myelomonocytic cells and checks that immature cells called blasts are below 20 percent, which separates JMML from acute leukemia. Genetic testing of blood cells for the RAS-pathway genes is central. It confirms the diagnosis, and testing other tissue can show whether a gene change was inherited, which affects treatment. Because some infections and other conditions can mimic JMML, these are ruled out. Many centers also use a laboratory test of DNA methylation patterns to estimate how aggressive the disease is likely to be.

Treatment Options

For most children, an allogeneic stem cell transplant (also called a bone marrow transplant) is the only treatment proven to cure JMML. Strong chemotherapy first clears the child's own blood-forming system, and stem cells from a matched donor then rebuild it. The donor's immune cells also help attack remaining leukemia cells. Transplant is demanding: it usually means weeks in hospital while the new marrow takes hold, and it carries serious risks, some of them life-threatening, alongside its chance of cure. Before transplant, children often receive azacitidine (Vidaza), a chemotherapy drug that changes how genes are switched on in leukemia cells. It is FDA-approved for children 1 month and older with newly diagnosed JMML and is used to bring the disease under better control on the way to transplant. Other chemotherapy may be used for the same purpose. Not every child needs a transplant. Some forms, particularly in children born with a CBL gene change or with Noonan syndrome, and some NRAS-related cases with favorable features, can settle down on their own. For these children, doctors may recommend careful observation instead, with regular blood counts and exams. The abnormal cells usually persist at a low level, so monitoring continues for years. If JMML returns after transplant, options include a second transplant and clinical trials of targeted drugs such as trametinib, which blocks a step in the RAS pathway.

What to Expect

The outlook for JMML depends heavily on the gene change involved, the child's age, platelet count and other features. For children who need a transplant, recent results show roughly two-thirds to three-quarters are alive five years later. Relapse after transplant, which happens in about one in five to one in three children, is the main reason treatment fails, so the months after transplant involve close follow-up. Children whose disease resolves on its own often do well, but they also need ongoing monitoring. Treatment usually happens at a children's cancer center and can take over family life for months, with long hospital stays, frequent clinic visits and periods when the child must avoid infections. Many hospitals offer social workers, child life specialists and family support. After treatment, children have long-term follow-up for blood counts, relapse and late effects of treatment, which can include problems with growth and bone development, hormone, heart or lung function, fertility, learning and, rarely, second cancers. Because JMML is rare, many children are treated on or alongside international study protocols.

When to Seek Help

See a doctor if a young child has a swollen belly, ongoing paleness or tiredness, unexplained bruising or tiny red spots under the skin, repeated fevers, swollen lymph nodes or a persistent rash. These signs have many causes, but a blood count can quickly show whether further testing is needed. Children with Noonan syndrome or neurofibromatosis type 1 should have such signs checked promptly. During and after treatment, the care team will give specific instructions about fever, bleeding and breathing problems. Follow those instructions and call the team right away for any of these signs, since infections and bleeding can become serious quickly when blood counts are low.

Questions to Ask Your Doctor

  1. 1.Which gene change does my child's JMML have, and was it inherited or did it arise only in the blood cells?
  2. 2.Does my child need a stem cell transplant, or is observation a reasonable option for this subtype?
  3. 3.What would treatment before transplant involve, and how will we know whether it is working?
  4. 4.What are the main risks of transplant for my child, and how is relapse watched for afterward?
  5. 5.If the gene change is inherited, should other family members be tested or followed?

Last reviewed • Oct 2026

Educational content, not medical advice.